A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Gemcitabine|DRUG: Oxaliplatin
Sponsor: Emory University
Collaborators: Sanofi